VAUGHAN & Co SECURITIES INC. Purchases 8,370 Shares of Pfizer Inc. (NYSE:PFE)

VAUGHAN & Co SECURITIES INC. grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 43.6% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 27,570 shares of the biopharmaceutical company’s stock after purchasing an additional 8,370 shares during the quarter. Pfizer accounts for 0.5% of VAUGHAN & Co SECURITIES INC.’s holdings, making the stock its 21st largest position. VAUGHAN & Co SECURITIES INC.’s holdings in Pfizer were worth $771,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of PFE. FAS Wealth Partners Inc. increased its position in Pfizer by 1.3% in the second quarter. FAS Wealth Partners Inc. now owns 26,306 shares of the biopharmaceutical company’s stock worth $736,000 after purchasing an additional 342 shares during the last quarter. Ironvine Capital Partners LLC increased its position in Pfizer by 2.1% in the first quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock worth $470,000 after purchasing an additional 353 shares during the last quarter. Secure Asset Management LLC increased its position in Pfizer by 0.6% in the second quarter. Secure Asset Management LLC now owns 58,328 shares of the biopharmaceutical company’s stock worth $1,632,000 after purchasing an additional 353 shares during the last quarter. Patrick M Sweeney & Associates Inc. increased its position in Pfizer by 0.8% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 42,162 shares of the biopharmaceutical company’s stock worth $1,180,000 after purchasing an additional 355 shares during the last quarter. Finally, Continuum Advisory LLC increased its position in Pfizer by 1.5% in the second quarter. Continuum Advisory LLC now owns 25,185 shares of the biopharmaceutical company’s stock worth $705,000 after purchasing an additional 360 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on PFE. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, August 19th. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. UBS Group lifted their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Finally, Barclays upped their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Stock Up 1.0 %

Pfizer stock traded up $0.29 during midday trading on Friday, hitting $29.01. 37,137,599 shares of the company’s stock were exchanged, compared to its average volume of 38,496,418. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $36.29. The firm has a 50-day moving average of $28.99 and a two-hundred day moving average of $28.01. The company has a market cap of $164.39 billion, a PE ratio of -483.50, a P/E/G ratio of 0.98 and a beta of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.67 earnings per share. As a group, analysts expect that Pfizer Inc. will post 2.68 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.79%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s payout ratio is -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.